Compare OPLN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | ACAD |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2008 | 2000 |
| Metric | OPLN | ACAD |
|---|---|---|
| Price | $35.46 | $28.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 22 |
| Target Price | ★ $32.00 | $30.55 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.67 | 0.20 |
| Revenue | ★ $1,934,500,000.00 | $726,437,000.00 |
| Revenue This Year | $9.43 | $18.80 |
| Revenue Next Year | $6.80 | $11.70 |
| P/E Ratio | ★ $51.82 | $141.35 |
| Revenue Growth | 8.16 | ★ 40.45 |
| 52 Week Low | $25.81 | $19.69 |
| 52 Week High | $42.69 | $30.96 |
| Indicator | OPLN | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 48.65 |
| Support Level | $34.19 | $27.90 |
| Resistance Level | $35.92 | $30.96 |
| Average True Range (ATR) | 0.92 | 0.84 |
| MACD | 0.17 | -0.29 |
| Stochastic Oscillator | 57.30 | 2.18 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.